High Risk Acute Myeloid Leukemia Clinical Trials

14 clinical trials for High Risk Acute Myeloid Leukemia across international registries, including 7 currently recruiting participants. Compare status, phase, eligibility criteria and locations.

• Phase 1/2: CD45RA Depleted Stem Cell Addback to Prevent Viral or Fungal Infections Post TCRab/CD19 Depleted HSCT — RECRUITING · PHASE1
• Clinical Study to Evaluate the Safety and Efficacy of γδ T Cells for the Prevention of Relapse After Allogeneic Transplantation in Patients With High-risk Acute Myeloid Leukemia — RECRUITING · NA
• Novel Digital Application for Patients With Acute Leukemia — RECRUITING · NA
• Venetoclax-Enhanced BUCY vs. Standard BUCY Conditioning in High-Risk AML and MDS Patients Undergoing Allo-HSCT (Ven-BUCY Study) — RECRUITING · NA
• Specialty Compared to Oncology Delivered Palliative Care for Patients With Acute Myeloid Leukemia — RECRUITING · NA
• Thiotepa Combined With Busulfan and Fludarabine Conditioning Regimen for Haploidentical Hematopoietic Stem Cell Transplantation in Elderly Patients With High-Risk Acute Myeloid Leukemia — RECRUITING · PHASE2
• Study of VA Combined With HAAG Regimen in Newly Diagnosed Intermediate and High-risk AML Patients — RECRUITING · PHASE2
• Busulfan, Fludarabine Phosphate, and Post-Transplant Cyclophosphamide in Treating Patients With Blood Cancer Undergoing Donor Stem Cell Transplant — ACTIVE_NOT_RECRUITING · PHASE2
• Effect of Donor Chose on the Outcomes of GVHD Prophylaxis Underwent the Combined Treatment of ATG/PTCy for Haplo-HSCT — NOT_YET_RECRUITING
• CBA Versus FBA Conditioning Followed by Haploidentical Allogeneic HSCT in Treatment of High Risk and Refractory AML — OTHER · PHASE3
• CBA Versus FBA Conditioning Followed by Allogeneic HSCT in Treatment of High Risk and Refractory AML — OTHER · PHASE3
• Ex-vivo Primed Memory Donor Lymphocyte Infusion to Boost Anti-viral Immunity After T-cell Depleted HSCT — OTHER · PHASE1
• Phase III Study of CPX-351 Versus 7+3 in Patients 60-75 Years Old With Untreated High Risk (Secondary) Acute Myeloid Leukemia — COMPLETED · PHASE3
• QUILT-3.034: Non-Myeloablative TCRa/b Deplete Haplo HSCT With Post ALT-803 for AML — WITHDRAWN · PHASE2

Refine this search